References
- Sun L, Zhu Y, Qian Q, et al. Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis. Medicine (Baltimore). 2018;97(26):e11220. doi:10.1097/MD.000000000001122029952978
- Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol. 2018;4(6):798–804. doi:10.1001/jamaoncol.2018.013729621380
- Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20(4):1128–1143. doi:10.1200/JCO.2002.20.4.112811844838
- Gourd E. Sarcopenia and adiposity linked to overall survival. Lancet Oncol. 2018;19(5):p. e239. doi:10.1016/S1470-2045(18)30284-5
- van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2569–2578. doi:10.1158/1055-9965.EPI-09-037219755644
- Iwase T, Sangai T, Nagashima T, et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med. 2016;5(1):41–48. doi:10.1002/cam4.57126626021
- Del Fabbro E, Parsons H, Warneke CL, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240–1245. doi:10.1634/theoncologist.2012-016922903527
- Deluche E, Leobon S, Desport JC, et al. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer. 2018;26(3):861–868. doi:10.1007/s00520-017-3902-628948392
- Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. Eur J Surg Oncol. 2017;43(4):613–618. doi:10.1016/j.ejso.2016.09.02027793416
- Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013;24(12):2990–2994. doi:10.1093/annonc/mdt36424013581
- Pennisi A, Kieber-Emmons T, Makhoul I, et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer (Auckl). 2016;10:103–106. doi:10.4137/BCBCR.S3316327478380
- Burhans MS, Hagman DK, Kuzma JN, et al. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol. 2018;9(1):1–58. doi:10.1002/cphy.c17004030549014
- Rausch LK, Hofer M, Pramsohler S, et al. Adiponectin, leptin and visfatin in hypoxia and its effect for weight loss in obesity. Front Endocrinol (Lausanne). 2018;9:615. doi:10.3389/fendo.2018.0061530405530
- Himbert C, Delphan M, Scherer D, et al. Signals from the adipose microenvironment and the obesity-cancer link-a systematic review. Cancer Prev Res (Phila). 2017;10(9):494–506. doi:10.1158/1940-6207.CAPR-16-032228864539
- Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26(25):4072–4077. doi:10.1200/JCO.2007.14.452718757321
- Erbes T, Stickeler E, Rücker G, et al. BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer. 2016;16(4):e119–32. doi:10.1016/j.clbc.2016.02.01827067040
- Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol. 2013;2013:906495. doi:10.1155/2013/90649523431300
- Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–621. doi:10.1001/jamaoncol.2015.154626182172
- Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. doi:10.1016/j.ejca.2015.12.03026882087